Target intelligence / Profile preview

Influenza B virus hemagglutinin (HA0) (HA0)

Target
HA0
Molecular classification
Viral surface glycoprotein, Class I viral fusion protein, Receptor
01

Overview

Influenza B virus hemagglutinin (HA) is a major surface glycoprotein and a critical mediator of viral infectivity, synthesized as a precursor polypeptide called HA0. For the virus to become infectious, HA0 must undergo proteolytic cleavage by host cell proteases into two subunits, HA1 and HA2, which are essential for receptor binding and membrane fusion, respectively. The HA1 subunit recognizes and binds to sialic acid-containing receptors on the host cell surface to initiate endocytosis, while the HA2 subunit undergoes a dramatic conformational change at low pH to fuse the viral and endosomal membranes. As the primary target of the host's neutralizing antibody response, HA0 is the central antigen in both inactivated and live-attenuated influenza vaccines. Modern drug development efforts target conserved regions of the HA0 stem or the cleavage site to create universal vaccines and broad-spectrum antivirals that can bypass the challenges of antigenic drift.

Other names
Hemagglutinin precursorInfluenza B HAHA0 proteinHA0 peptideHemagglutininInfluenza B virus HA0
02

Mechanism of action

Inhibition of viral entry by blocking the attachment of the HA1 subunit to host sialic acid receptors or by preventing the proteolytic cleavage of HA0 into its functional subunits, thereby inhibiting the pH-dependent membrane fusion mediated by the HA2 subunit.

03

Biological functions

Host cell surface receptor bindingMembrane fusionViral entryImmune response induction
04

Disease associations

Infection
05

Safety considerations

Antigenic drift and shift leading to immune evasionInefficient proteolytic cleavage in recombinant vaccine production systemsPotential for vaccine mismatch with circulating seasonal strains
06

Interacting drugs

Quadrivalent influenza vaccine

5 more in the full profile.

07

Biomarkers

Hemagglutination inhibition (HAI) titersMicroneutralization titersSerum IgG levels against HA0

Beyond the preview

Go deeper on Influenza B virus hemagglutinin (HA0) (HA0).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Influenza B virus hemagglutinin (HA0) (HA0).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call